BTR Capital Management Inc. trimmed its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 1.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,745 shares of the medical research company’s stock after selling 827 shares during the quarter. Thermo Fisher Scientific comprises 2.6% of BTR Capital Management Inc.’s portfolio, making the stock its 7th largest position. BTR Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $12,817,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC grew its holdings in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 253 shares during the period. Chicago Partners Investment Group LLC purchased a new stake in Thermo Fisher Scientific during the second quarter worth approximately $108,000. Cribstone Capital Management LLC grew its stake in Thermo Fisher Scientific by 8.7% during the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after buying an additional 50 shares during the period. Shine Investment Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter worth approximately $113,000. Finally, Ropes Wealth Advisors LLC grew its stake in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 97 shares during the period. Hedge funds and other institutional investors own 85.32% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) is BTR Capital Management Inc.’s 7th Largest Position” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.truebluetribune.com/2017/11/21/thermo-fisher-scientific-inc-tmo-is-btr-capital-management-inc-s-7th-largest-position.html.
Thermo Fisher Scientific Inc (NYSE:TMO) opened at $191.00 on Tuesday. The firm has a market cap of $76,180.00, a price-to-earnings ratio of 20.90, a PEG ratio of 1.74 and a beta of 1.08. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.03 earnings per share. analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.19%.
In related news, VP Seth H. Hoogasian sold 4,140 shares of the company’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the sale, the vice president now directly owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel P. Shine sold 2,026 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $366,645.22. Following the completion of the sale, the insider now directly owns 20,682 shares in the company, valued at $3,742,821.54. The disclosure for this sale can be found here. Insiders sold 60,420 shares of company stock worth $11,308,477 over the last ninety days. 0.49% of the stock is currently owned by corporate insiders.
Several equities research analysts have issued reports on the stock. Deutsche Bank AG set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Leerink Swann boosted their price objective on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. Cowen and Company reiterated an “outperform” rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Finally, Barclays PLC reiterated an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $205.71.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.